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Abstracts 6 
 7 
Introduction: to describe antithrombotic-related major haemorrhage, therapeutic 8 
management and outcomes in patients admitted to an emergency department of a teaching 9 
hospital. 10 
Material and method: This prospective cohort included patients older than 16 years with 11 
antithrombotic-related major haemorrhage identified by monthly diagnostic codes 12 
computerised requests. Major haemorrhage was defined by at least one the following criteria: 13 
unstable hemodynamic, haemorrhagic shock, uncontrollable bleeding, need for transfusion or 14 
haemostatic procedure, or a life threatening location. 15 
Results: between January 1, 2011 and December 31, 2012, 913 patients met the inclusion 16 
criteria (1.2 patients per day), median age 82. Oral anticoagulants alone or in combination 17 
were used by 429 patients, antiplatelet agents (alone or dual therapy) by 420 patients, and 18 
parenteral anticoagulants by 64 patients. Major haemorrhages were: gastrointestinal bleeding 19 
(37.5%), intracranial haemorrhage (34.4%), muscular hematoma (9.4%), external 20 
haemorrhage (16.9%) and internal haemorrhage (1.9%). At 1 month, 179 patients (19.8%) 21 
died, mostly patients with intracranial haemorrhage (64.2%). Prognostic factors for death 22 
were age and Glasgow coma scale at admission for intracranial haemorrhage, age and mean 23 
arterial pressure at admission for other major haemorrhages. Oral anticoagulant therapy was a 24 
predictor for death in intracranial haemorrhages. Reversal therapy was initiated in only 50.5% 25 
of patients with vitamin K antagonists, without effect on the mortality rate.  26 
Conclusion: This study shows the magnitude and the severity of antithrombotic-related major 27 
haemorrhage. The high mortality rate supports careful awareness in individual risk benefit 28 
assessment, especially for elderly. 29 
 30 
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Introduction 6 
 7 
Antithrombotics, i.e. oral and parenteral anticoagulants as well as antiplatelet agents, have 8 
demonstrated significant benefits in preventing venous or arterial thrombotic events, 9 
especially in coronary disease, stroke, atrial fibrillation, venous thromboembolism and 10 
mechanical heart valves [1]. These drugs are commonly prescribed and their long term use is 11 
increasing, particularly in elderly.  12 
 13 
Bleeding represent the most well-known and feared complications of antithrombotics. 14 
Numerous studies on adverse drug events reported anticoagulants as the first medication class 15 
implicated in haemorrhage and specifically intracranial haemorrhage (ICH) which often 16 
results in substantial morbidity and mortality [2]. Using adverse drug events from a National 17 
Surveillance System, Budnitz et al demonstrated that warfarin and oral antiplatelet agents are 18 
respectively the first and the third medications leading to emergency department and 19 
hospitalization in adults 65 years of age or older [3]. For antiplatelet agents, gastrointestinal 20 
bleeding and intracranial haemorrhage are well known [4-6]. 21 
 22 
Emergency departments are unique to describe antithrombotic-related major haemorrhage. 23 
We report the results of a prospective cohort that aimed to describe antithrombotic-related 24 
major haemorrhage, diagnostic process, clinical and therapeutic management as well as 1-25 
month outcome.  26 
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 45 
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Material and methods 1 
 2 
Patient selection and definitions 3 
 4 
Patients older than 16 years admitted in the emergency department of our teaching hospital 5 
with antithrombotic-related major haemorrhage were consecutively included between January 6 
1, 2011 and December 31, 2012. Patients were identified through haemorrhagic symptoms at 7 
emergency admission. Computerised requests based on several related-haemorrhagic 8 
diagnostic codes and specific emergency therapies were made every month on electronic 9 
health records. Then, criteria of major bleeding were required and antithrombotic treatment 10 
searched. 11 
 12 
According to the French  National Authority for Health ( Haute Autorité de Santé - HAS) [7], 13 
major bleeding was defined by at least one of the following criteria :  hemodynamic instability  14 
(systolic arterial pressure < 90 mmHg or mean arterial pressure < 65 mm Hg), signs of shock, 15 
uncontrollable bleeding, need for transfusions of red cell packs, need for haemostatic 16 
procedure (embolization, endoscopic procedure, surgery), or a life-threatened bleeding such 17 
as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, thoracic  bleeding, 18 
compressive muscular hematoma, acute gastrointestinal bleeding. In addition to these criteria, 19 
we considered major bleeding in case of epistaxis if at least two procedures of nasal packing 20 
were needed and in case of hematuria if the bleeding continued during more than 12 hours 21 
despite bladder washing.  22 
All antithrombotic drugs, alone and in combination were eligible whatever their indication 23 
and their dosage.  24 
 25 
Patients with major bleeding events associated with antithrombotic during hospitalization, 26 
patients with intentional overdose with antithrombotic drugs and patients with multi-trauma 27 
were excluded.  28 
 29 
For all included patients, the following clinical and biological data were collected from 30 
electronic health record:  demographics, medical history, treatments with their indication and  31 
duration, type of bleeding manifestation, vital signs at admission, contributory procedures that 32 
led to diagnostic of major bleeding (CT scan, endoscopy) , biological data on admission, 33 
treatments done in the emergency ward, blood transfusions, specific reversal treatment, 34 
haemostatic procedure, time between admission and diagnosis, time between admission and  35 
reversal therapy, outcomes, length of  stay in hospital, and decision about antithrombotic 36 
treatment after the haemorrhagic event. At 1 month, clinical data about hemorrhagic or 37 
ischemic event and vital status were asked. 38 
 39 
The study protocol was approved by the ethical committee of our hospital. 40 
 41 
Data processing and analysis 42 
 43 
Three subgroups were defined depending on antithrombotic medications: group1: Oral 44 
anticoagulant (OA) group including patients with oral vitamin K antagonist and new oral 45 
anticoagulant, alone and in combination with other antithrombotic drugs; group 2: 46 
Antiplatelet (AP) group including patients with antiplatelet therapy only, either alone or dual 47 
therapy; group 3:  Parenteral anticoagulant (PA) group including patients with unfractionated 48 
heparin (UFH), low molecular weight heparin (LMWH), fondaparinux,  danaparoid, alone 49 
and in combination with antiplatelet therapy. 50 
 5 
Haemorrhagic events were firstly divided in 5 groups: intracranial haemorrhage, 1 
gastrointestinal bleeding, muscular hematoma, internal bleeding including pericardial, 2 
thoracic, peritoneal bleeding, and external bleeding including hematuria, epistaxis, scalp 3 
injury, vascular injury. Then, two subgroups were defined: patients with intracranial 4 
haemorrhage and patients with other major bleeding 5 
 6 
The primary outcome was 1-month mortality. 7 
 8 
Between subgroups comparisons were performed using student’s t test for parametric data, 9 
Mann-Whitney U test for non parametric data, and the chi-square test for qualitative data. 10 
Crude relative risks were estimated along with 95% confidence interval. Prognostic factors for 11 
death at 1-month were defined in the overall population and in the subgroups of patients with 12 
intracranial haemorrhage and patients with other bleeding than intracranial haemorrhage. 13 
Multivariate logistic models were run in subgroups of patients with intracranial haemorrhage 14 
and of patients with other major bleeding to assess the predictors of death. Statistical analysis 15 
was conducted using SAS software version 9.3 (SAS Institute Inc, Cary, NC, USA). A p 16 
value of .05 was considered statistically significant.  17 
 18 
19 
 6 
Results 1 
 2 
Population characteristics 3 
 4 
In 2011 and 2012, 98,377 adult patients were admitted in our emergency department. Nine 5 
hundred and thirteen patients (0.9%) with major bleeding while receiving at least one 6 
antithrombotic drug were analysed, which represented 1.2 patients per day. During the study 7 
period, there were no monthly variations.   The mean age was 80 ± 10 years ( range : 21-103); 8 
median, 82 years) with a sex ratio of 1.1.  Hospitalization was required for 728 patients (79%) 9 
with a mean length of stay of 8.5 ± 14.2 days,  including 1.3 ± 3.9 days in intensive care units. 10 
 11 
Demographic characteristics and indications of antithrombotics, according to the therapeutic 12 
subgroups, are reported in table 1. Among 913 patients, 152 (17.2%) had a combination of 13 
antithrombotic agents. The duration of prescription was unknown in 46.3% of cases.  14 
Gastrointestinal bleeding and intracranial haemorrhage (ICH) represented more than 70% of 15 
major haemorrhagic events (table 2). There was a statistically significant association between 16 
types of antithrombotics and types of haemorrhage (p < .0001): AP-related haemorrhages 17 
were mostly ICH (n = 164, 39%) and gastrointestinal bleeding (n = 179, 42%) whereas OA-18 
related haemorrhages were mostly external haemorrhages or muscular hematomas (n = 147, 19 
34%), gastrointestinal bleeding (n = 140, 33%) and ICH (n = 134, 31%). 20 
The mechanism of the ICH, known in 307 patients, was traumatic in 44.6% of cases, mostly a 21 
fall from standing height, spontaneous in 45.6%, impossible to determine in 9.4%. In 22 
traumatic ICH, there were more patients with AP than OA (60% versus 40%). Frequencies of 23 
AP and OA were similar in those patients with spontaneous ICH (51.5% versus 48.5%).  24 
 25 
Predictors of 1-month mortality 26 
 27 
At 1 month, data from 903 documented medical records were analysed.  In this population, 28 
179 patients died at 1 month (19.8 %). Fifty-five patients died in the emergency ward. 29 
Death occurred within the first 3 days of hospitalization in 81 patients. The distribution of 30 
death according to the type of haemorrhagic events showed that intracranial haemorrhage was 31 
responsible of the most number of death (115/179 patients, 64.2%). Among 267 patients with 32 
a known ICH mechanism and a known vital status at 1 month, 1-month mortality was higher 33 
in spontaneous ICH than in traumatic ICH: 45.9% (62/135) vs. 26.5% (35/132), p = 0.001.  34 
Among 314 patients with ICH, 27 (8.6%) had limitation of life support; 22 patients (7.7%) out 35 
of the 287 remaining patients underwent surgery: 18 out of those 22 patients were alive at one 36 
month (81.8%) compared to 178 out of 265 patients who did not have surgery (67.2%), p = 37 
0.15. Among 342 patients with GI bleeding, 61 had an invasive therapy (endoscopy, n = 42; 38 
surgery, n = 20; embolisation, n = 3; of note 4 patients had two procedures); 59 out of those 39 
61 patients were alive at one month (96.7%) compared to 249 out of 281 patients who did not 40 
have invasive therapy (88.6%), p = 0.055.One-month mortality was not associated with the 41 
type of antithrombotic agents (table 3). 42 
In univariate analysis, prognostic factors for 1-month mortality in case of intracranial 43 
haemorrhage were age, Glasgow coma scale (GCS) score, the type of antithrombotic agents 44 
(OA), time between admission and diagnosis and time between admission and biological 45 
results (table 4). OA was associated with a 1.4-fold increased risk for 1-month mortality 46 
compared to AP: RR = 1.5 (95%CI, 1.1 to 2.0); relative risk for PA compared to AP was 1.2 47 
(95%CI, 0.6 to 2.5). Prognostic factors for 1-month mortality after other haemorrhagic events 48 
were age, mean arterial pressure at admission and type of antithrombotic agents (table 4). PA 49 
 7 
was associated with a 1.7-fold increased risk for 1-month mortality compared to AP: RR = 1.7 1 
(95%CI, 0.8 to 3.3); relative risk for OA compared to AP was 0.8 (95%CI, 0.5 to 1.4). 2 
Adjusting for age and GCS through multivariate logistic regression, OA remained statistically 3 
associated with ICH 1-month mortality compared to AP (p = 0.0451) and PA did not reached 4 
statistical significance for other haemorrhagic event 1-month mortality compared to AP (p = 5 
0.57).  6 
Among surviving patients at 1 month (724), antithrombotic treatment was continued without 7 
modifications in 382 patients (52.8%), with modifications in 125 patients (17.3%), 8 
discontinued in 171 patients (23.6%), not determined in 46 patients (6.3%). Antithrombotic 9 
treatment was stopped in all patients with ICH.  10 
 11 
Oral anticoagulant group: characteristics, clinical and therapeutic management 12 
 13 
Demographic and clinical characteristics of the 3 treatment groups are reported in table 5.  14 
Most of oral anticoagulants were vitamin K antagonists (427/429). Vitamin K antagonists 15 
were fluindione in 68% of cases, warfarine in 38% of cases and acenocoumarol in 3% of 16 
cases. In 63 patients, OA was in combination with AP. Only two patients were taking new 17 
oral anticoagulant (dabigatran etexilate) for prevention of stroke in atrial fibrillation and they 18 
were included at the end of 2012: a 82 years old man with major fatal hematuria, and a 80 19 
years old man with gastrointestinal bleeding, alive at 1 month.  20 
  21 
At admission, the international normalized ration (INR) was in the therapeutic range (between 22 
2 and 3) in 41.9% of cases, under the range in 18.6% and above in 39.5%. Median [p25-p75] 23 
INR value was slightly higher among patients with ICH who died within one month compared 24 
to those who were alive: 2.6 [2.1-3.2] vs. 2.4 [1.9-2.9] (p = 0.066). The same pattern was 25 
observed in other type of haemorrhage: 3.7 [2.4-7.4] vs. 2.8 [2.2-4.2] (p = 0.031). 26 
Reversal therapy was initiated in only 215 patients (50.5%); the complete recommended 27 
treatment, that is prothrombin complex concentrate (PCC) at a dose equal or superior to 20 28 
IU/kg in association with 5 or 10 mg of vitamin K, was prescribed only in 80 patients 29 
(19.1%). This reversal treatment was not significantly associated with 1-month mortality 30 
considering only patients with no limitation of life support: 5/21 (23.8%) vs. 11/40 (27.5%) in 31 
patients with ICH and 6/70 (8.6%) vs. 7/68 (10.3%) for other type of haemorrhage. 32 
 33 
Two-hundred and two patients needed blood transfusions (mean 2.3 units of red cells), for 34 
gastrointestinal bleeding in 101 patients, muscular hematomas in 39 patients, epistaxis in 17 35 
patients. Fifty patients required surgery. 36 
At 1 month, OA therapy was continued in 53% of cases and stopped in 24% of cases. In 23% 37 
of cases, treatment was changed, switch with antiplatelet agents or stop of combination. 38 
 39 
Antiplatelet group: characteristics, clinical and therapeutic management 40 
 41 
In the antiplatelet group (420 patients), aspirin represented 88% of cases, clopidogrel 20% of 42 
cases, dual therapy 9% of cases. Demographic and clinical characteristics, number of red cell 43 
transfusions, hospitalization rate and mortality rate were not different compared to patients 44 
from the oral anticoagulant group (table 5). No platelet transfusion was prescribed.  45 
At 1 month, antiplatelet agents were continued in 61% of cases, discontinued in 24% of cases. 46 
In 15% of cases, the treatment was modified, that is stop of the dual therapy or switch with 47 
other antiplatelet drugs. 48 
 49 
Parenteral anticoagulant group: characteristics, clinical and therapeutic management 50 
 8 
 1 
In the parenteral anticoagulant group (64 patients), drugs were: LMWH in 43 patients, UFH 2 
in 5 patients, fondaparinux in 15 patients and danaparoid in one patient; the dose was curative 3 
in 37 patients (57.8%), mainly with LMWH (n = 23) and fondaparinux (n = 10) whereas only 4 
four patients had curative UFH dose. The main indication was the venous thromboembolic 5 
disease. Glasgow coma scale score, mean arterial pressure, mean haemoglobin level at 6 
admission were different with patients of other groups (not significant). No reversal treatment 7 
(protamin sulfate) was initiated. At 1 month, parenteral anticoagulants were continued in 22 8 
patients, stopped in 20 patients.  9 
10 
 9 
Discussion 1 
 2 
With more than one patient per day admitted in our emergency ward on a two-year period, our 3 
study highlighted the magnitude of major bleeding associated with antithrombotics, whatever 4 
the antithrombotic drug. 5 
 6 
The patient’s median age was high (82 years old), reflecting the increasing use of 7 
antithrombotic in elderly in all their indications, as previously reported [4].  Particularly, the 8 
number of patients with atrial fibrillation will progressively increase in the next years. 9 
Consequently, the number of major bleeding will still increase in this frail population, leading 10 
to an important morbidity and mortality. Despite this increased haemorrhagic risk secondary 11 
to age, the elderly still have the most important benefits of antithrombotics, even after a major 12 
bleeding event [8]. In survivors, we observed that 53 % of the oral anticoagulant group and 13 
61% of the antiplatelet group continued the same antithrombotic treatment 1 month after the 14 
haemorrhagic event.  15 
 16 
In our study, 152 patients were taking more than one antithrombotic drugs with various 17 
combinations. Even if the combination of antithrombotics increase the haemorrhagic risk [9, 18 
10] the various combination would have complicated the analysis of our study population. 19 
Thus, to compare the different antithrombotic agents, we classified our patients in only three 20 
therapeutic groups, considering that the haemorrhagic risk was most important with oral and 21 
parenteral anticoagulants than with antiplatelet agents [1, 11]. We identified 64 patients with 22 
major bleeding associated with parenteral anticoagulant, especially heparins and 23 
fondaparinux. To our knowledge, this was the first report on major bleeding in an ambulatory 24 
population with these antithrombotics. Usually, most data came from multicenter clinical trial 25 
[13]. Our results showed that the corresponding population was different from patients of 26 
others therapeutic groups, i.e. more severity, increased mortality rate in patients with mainly 27 
venous thromboembolic indication.  In this group, the distribution of the different 28 
haemorrhagic complications was equivalent to other group of antithrombotics, as previously 29 
reported [14]. 30 
 31 
In the therapeutic management of the hemorrhagic events, there were an important number of 32 
blood transfusions, with numerous haemostatic procedures (surgery, endoscopic procedure). 33 
Indications of blood transfusions were left to physician appreciation.  In the oral anticoagulant 34 
group, reversal therapy was used in only 50.5 % of cases, despite the national guidelines [7]. 35 
In ICH associated with oral anticoagulant, reversal therapy with PCC and vitamin K was 36 
specially used because of the poor prognosis of this bleeding event. Nevertheless, the 37 
mortality rate was not different with or without reversal therapy in case of ICH. In the 38 
antiplatelet group, no platelet transfusion was needed, according to the recent systematic 39 
review in traumatic and spontaneous ICH [15]. 40 
 41 
Gastrointestinal bleeding was the first major haemorrhagic events in our study, with a similar 42 
number associated with OA and AP. Even if this bleeding risk was well known, international 43 
trial and meta-analysis have reported various risk levels according to the antithrombotic 44 
drugs. Relative risk of gastrointestinal risk was estimated at 1.8 and 1.6 for respectively 45 
aspirin and clopidogrel, two-fold higher for oral anticoagulant therapy, especially when the 46 
INR value is high [5, 16, 17]. In our OA group, INR value was not a prognostic factor. 47 
Dangerous combinations such as OA + AP or dual antiplatelet therapy induced a more 2-fold 48 
higher risk of gastrointestinal bleeding [10, 12]. 49 
 50 
 10 
In 314 patients (34.4 %), the haemorrhagic event was intracranial, spontaneous or traumatic, 1 
leading to a dramatic prognosis (64.2% of dead patients at 1 month had IHC). The number of 2 
patients with OA and AP was similar, but, the multivariate OR for death in ICH patients was 3 
significantly unfavourable at one month  in OA versus AP (OR = 1.89 (95%CI 1.01-3.54). 4 
This high mortality has been reported elsewhere [18, 19] and seemed to be dependant to the 5 
mechanism of the ICH and to the antithrombotic medication. In a multicenter Italian study in 6 
emergency departments, Baldi and al reported a mortality rate of 44% in post traumatic IHC 7 
(41% with AP and 51% with OA), and 58% in spontaneous ICH (51% with AP and 69% with 8 
OA [4]. Like others, we found that age and Glasgow coma scale will be strong prognostic 9 
factors in patients with intracranial haemorrhage. In case of ICH, time between admission and 10 
diagnosis and time between admission and first biological results were significantly shorter in 11 
patients who died, which could be explained by a more severe condition on admission.  12 
In head trauma, oral anticoagulant led to 10-fold higher incidence of intracranial 13 
haemorrhagic lesions (3 versus 29%), reaching a mortality rate near to 60% [20]. Old age 14 
increased furthermore this rate (OR = 1.2 for each increase of 10 years) [21]. As reported by 15 
Dowlatshahi et al [22] and as shown in our results, the mortality did not seem to be affected 16 
by complete reversal therapy. 17 
 18 
For antiplatelet drugs, there is a great heterogeneity for establishing a strong link between 19 
ICH and this medication, because of various inclusion criteria, different methodology, 20 
severity at inclusion, mechanism, outcomes. Nevertheless, antiplatelet drugs appeared to be a 21 
risk factor for IHC in patients with minor head trauma. In a recent meta-analysis, Bachelor et 22 
al [23] reported an important overall relative risk of aspirin in all head trauma (OR = 2.43), 23 
higher than clopidogrel (OR = 1.55); other studies have reported opposite results, with a more 24 
important risk with clopidogrel than with aspirin [24, 25]. Whatever these various risk 25 
assessments, the old age and the Glasgow coma score appeared to be strong prognosis factors, 26 
as shown in our results [26].  In spontaneous ICH, the systematic review of Thompson et al 27 
reported an increase of mortality rate induced by antiplatelet agents (40% in univariate 28 
analysis, 27% in multivariate analysis) and a higher poor prognosis (respectively 29 and 10%) 29 
[27]. 30 
 31 
Strengths 32 
 33 
The selection method used in our study would have contributed to increase the number of 34 
haemorrhagic events. We selected patients firstly from the haemorrhagic symptom at 35 
emergency admission, in contrast with most studies on this subject which screened patients 36 
from the medication. Our method was quite similar with the study reported by Budnitz et al, 37 
in which coders reviewed clinical records of each emergency department visit to identify 38 
adverse drug events [3]. Heterogeneity of codes compelled to use a list of about forty different 39 
diagnostic codes relative to haemorrhagic events and pathologies. This first step was then 40 
completed by the search for the criteria of major bleeding and finally by the identification of 41 
the antithrombotic medication, information often missed in the emergency medical record. 42 
This method could explain the equal number of major bleeding with oral anticoagulant and 43 
antiplatetet drugs, with a quite equivalent distribution of types of haemorrhage, particularly 44 
intracranial haemorrhage and gastrointestinal bleeding. In the same way, it could explain the 45 
relative important group of patients with parenteral anticoagulants. 46 
 47 
Limitations 48 
 49 
 11 
Our study was monocentric and in part retrospective. Computer requests were made every 1 
month in a retrospective manner, which could explain a lost of some data concerning medical 2 
history and antithrombotic duration.  However, this design could provide an unbiased 3 
observation of real life behaviour because patients’ management was not influenced by the 4 
knowledge of an ongoing study. Because of the heterogeneity of diagnostic codes, we listed 5 
about 40 different symptoms and diseases related to haemorrhagic events.  6 
We used criteria of major bleeding recommended by the French National Authority for Health 7 
(Haute Autorité de Santé -  HAS) [7] rather than criteria of the International Society on 8 
Thrombosis and Haemostasis (ISTH) defined by Schulman et al [28]. We thought that all 9 
these criteria were close to each other, which would not have modified our population. In 10 
addition, we thought that the fall in haemoglobin level of 20g/L or more is a less suitable 11 
criterion for an emergency recruitment.  12 
 13 
 14 
Conclusion 15 
  16 
Our study shows the magnitude of major bleeding in a very old population taking 17 
antithrombotics, admitted in the emergency department of a teaching hospital. Oral 18 
anticoagulants and antiplatelet drugs are equally implicated in this iatrogenic pathology. The 19 
severity is attested by a high mortality (about 20%) at one month after the haemorrhagic 20 
event. Intracranial haemorrhage, age and Glasgow coma scale at admission are prognostic 21 
factors. In case of intracranial haemorrhage, oral anticoagulant is a predictor of death.  22 
The high frequency of these events and the important mortality rate suggest a great vigilance 23 
in risk benefit imbalance of antithrombotic medication for individual patients, especially for 24 
elderly.  25 
 26 
 27 
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Table 1 Demographics and clinical characteristics.  9 
 10 
Patients   n % 
 Gender    
  Male  480 52.6 
  Female 433 47.4 
 Age, years    
  21 – 60  44 4.8 
  61 – 70  83 9 
  71 – 80  260 28.5 
  81 – 103  526 57.6 
 Indication of antithrombotics    
  Atrial fibrillation 371 51.6 
  Stroke  164 15.6 
  Myocardial infarction 162 24.7 
  Venous thromboembolism 115 15.7 
  Peripheral arterial disease 75 11.3 
  Mechanical heart valve 46 8.5 
  Others 121 16.3 
 Duration of antithrombotic medication    
  < 1 year 117 12.8 
  1 > years > 5 158 17.3 
  > 5 years 215 23.6 
  Unknown  423 46.3 
 Type of antithrombotic agents     
  Oral anticoagulant 
           Vitamin K antagonist 
                 alone 
                 in combination with antiplatelet 
                 other combination 
           New oral anticoagulant 
429 
427 
353 
61 
12 
2 
47.0 
46.8 
 
 
 
0.2 
  Antiplatelet agents 
           alone 
           dual therapy 
420 
380 
39 
46.0 
  Parenteral anticoagulant 64 7.0 
            Unfractionned heparin 
          Low molecular weight heparin 
          Fondaparinux 
          Danaparoid 
5 
43 
15 
1 
 
 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 16 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
Table 2  Distribution of haemorrhagic events 10 
 11 
Type of haemorrhage 
 
N % 
Gastrointestinal bleeding                                                                   
Intracranial haemorrhage                                                                
Muscular hematoma                                                                               
External haemorrhage                                                                                 
                       Epistaxis                                                                                 
                       Hematuria                                                                              
                       Scalp injury                                                                           
                       Vascular injury                                                                       
                       Other                                                                                    
Internal haemorrhage                                                                                       
                      Thoracic                                                                                  
                      Peritoneal                                                                                       
                      Pericardial                                                                                     
342 
314 
86 
154 
47 
36 
19 
11 
41 
17 
7 
6 
4 
37.5 
34.4 
9.4 
16.9 
5.1 
3.9 
2.1 
1.2 
4.5 
1.9 
0.8 
0.6 
0.4 
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 28 
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Table 3 Hemorrhagic events and antithrombotic drugs according to 1-month mortality 10 
 11 
 Dead patients  
N = 179 
 
Alive patients  
N = 724 
 
Haemorrhagic event n (%) n (%) < 0.0001 
Intracranial haemorrhage 115 (64.2)  199 (27.5)  
Gastrointestinal bleeding 34 (19.0) 308 (42.5)  
Muscular hematoma 8 (4.47) 73 (10.1)  
External haemorrhage 20 (11.2)  130 (18.0)  
Internal haemorrhage 2 (1.12) 14 (1.93)  
Treatment group   0.5592 
OA 87 (48.6) 335 (46.3)  
AP 77 (43.0) 340 (46.9)  
PA 15 (8.38) 49 (6.79)  
    
OA : oral anticoagulant ; AP : antiplatelet ; PA : parenteral anticoagulant; 12 
 13 
 14 
 15 
 16 
 17 
 18 
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 20 
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 24 
 25 
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 27 
 28 
 29 
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 31 
 32 
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 37 
 38 
 18 
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 19 
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Table 4 Prognostic factors of 1-month mortality in univariate analysis; A: in patients with 5 
intracranial haemorrhage (n=314). B: in patients with other haemorrhagic events (n=579)  6 
 7 
A 8 
Characteristic Died patients 
N = 115 
Alive patients  
N = 199 
 
Treatment   0.0293 
OA 60 (52.2) 74 (37.2)  
AP 49 (42.6) 115 (57.8)  
PA 6 (5.22) 10 (5.03)  
Clinical characteristics    
Female 60 (52.2) 101 (50.7) 0.8083 
Age, years 81.6 ± 8.8 79.4 ± 10.0 0.0545 
Glasgow coma scale 8 [3-15] 15 [3-15] < 0.0001 
Hemoglobin level, g/dL 13.1 ± 1.8 13.0 ± 1.7 0.8772 
Mean arterial pressure (mmHg) 107 ± 25 97 ± 18 0.0004 
Time admission/diagnosis (hours) 5.9 ± 9.8 9.4 ± 13.2 < 0.0001 
Time  admission/biological data (hours) 1.3 ± 1.7 2.7 ± 5.5 < 0.0001 
Reversal therapy  (VKA, n = 75) 17 (58.6) 29 (63.0) 0.7017 
 9 
 10 
B 11 
Characteristic Died patients  
N = 64 
Alive patients  
N = 525 
 
Treatment   0.1561 
OA 27 (42.2) 261 (49.7)  
AP 28 (43.7) 225 (42.8)  
PA 9 (14.1) 39 (7.46)  
Clinical characteristics    
Female 29 (45.3) 236 (44.9) 0.9564 
Age, years 83.2 ± 9.2 79.7 ± 10.5 0.0024 
Hemoglobin level, g/dL 8.7 ± 2.2 8.8 ± 2.3 0.7662 
Mean arterial pressure (mm Hg) 70 ± 19 78 ± 16 0.0034 
Time  admission/diagnosis (hours) 9.9 ± 14.8 7.9 ± 12.1 0.9162 
Time  admission/biological data (hours) 1.7 ± 1.3 1.9 ± 1.4 0.2147 
Reversal therapy  (VKA, n = 138) 6 (46.1) 64 (51.2) 0.7291 
 12 
OA : oral anticoagulant ; AP : antiplatelet ; PA : parenteral anticoagulant; VKA: vitamin K antagonist 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 20 
 1 
Table 5  Characteristics of patients according to therapeutic groups. 2 
 3 
Characteristics n (%) OA 
N = 429 
AP 
N = 420 
PA 
N = 64 
p-value 
Type of haemorrhage    <.0001 
Gastrointestinal bleeding 140 (32.6) 176 (41.9) 26 (40.6)  
      Intracranial haemorrhage 134 (31.2) 164 (39.0) 16 (25.0)  
      External haemorrhage 88 (20.7) 54 (12.8) 12 (18.7)  
Muscular hematoma 57 (13.3) 17 (4.0) 12 (18.7)  
Internal haemorrhage 7 (1.6) 9 (2.1) 1 (1.6)  
Indication      
Atrial fibrillation 304 (70.9) 55 (13.1) 12 (18.7)  
Stroke  48 (11.2) 106 (25.2) 12 (18.7)  
Myocardial infarction 45 (10.5) 108 (25.7) 11 (17.2)  
Venous thromboembolism 71 (16.5) 21 (5) 21 (32.8)  
Peripheral arterial disease 20 (4.6) 49 (11.7) 10 (15.6)  
Mechanical heart valve 36 (8.4) 10 (2.4) 0  
Others 8 (1.9) 97 (23.1) 20 (31.2)  
Duration of antithrombotic    <.0001 
< 1year 48 (11.2) 36 (8.6)       33(51.6)  
1> years >5 76 (17.7) 73 (17.4) 9 (14.1)  
> 5 years 100 (23.3) 108 (25.7) 5 (7.8)  
Unknown 202 (47.1) 202 (48.1) 18 (28.1)  
Clinical characteristic     
Female, n (%) 207 (48.2) 194 (46.2) 30 (46.9) 0.796 
Age, years 79.7 ± 10.3 80.8 ± 9.5 78.8 ± 12.8 0.279 
      GCS -  median [min-max] 15 [3-15] 15 [3-15] 14 [3 – 15] 0.347 
Mean arterial pressure (mmHg) 85 ± 22 87 ± 21 77 ±  20 0.001 
Haemoglobin level, g/dL 10.2 ± 2.9 10.3 ± 3.0 9.2 ± 2.3 0.028 
Reversal therapy  215 (50.1) - -  
Blood transfusion   
Number of units (mean) 
202 (47.1) 
2.3 
197 (46.9) 
2.0 
36 (56.2) 
1,5 
 
Hospitalization  337 (78.5) 337 (80.2) 58 (90.1)  
Mean length of stay (day) 8.5 ± 11.4 8.8 ± 17.9 9.1 ± 11.2 0.733 
     
Outcomes  at 1 month     0.345 
Lost of follow-up 7 (1.6) 3 (0.7) 0 (0)  
dead 87 (20.3) 77 (18.3) 15 (23.4)  
alive 335 (78.0) 340 (80.9) 49 (76.5)  
OA= oral anticoagulant; AP= antiplatelet; PA= parenteral anticoagulant. GCS: Glasgow coma scale, in patients 4 
with intracranial haemorrhage 5 
 6 
 7 
